Evidence map›Paper›PMID 31345785›Full record

ArticleEBioMedicine2019

Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.

Yijin Wang, Huiying Rao, Xiumei Chi, Boan Li, Hongyang Liu, Liyuan Wu, Hao Zhang, Shuhong Liu, Gaungde Zhou, Na Li and 3 more

Abstract read
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. CD14Experimental and therapeutic medicine · 2020
    Article
  18. [Analytical value of histological research and application of RNAscope technology in liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Yijin WangDepartment of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China.
Huiying RaoPeking University Hepatology Institute, Peking University People's Hospital, Peking University Health Science Center, Beijing, China.
Xiumei ChiDepartment of Hepatology, the First Hospital of Jilin University, Changchun, China.
Boan LiCenter for Clinical Laboratory, the 5th Medical Center, Chinese PLA General Hospital, China.
Hongyang LiuDepartment of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China.
Liyuan WuDepartment of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China.
Hao ZhangCenter for Clinical Laboratory, the 5th Medical Center, Chinese PLA General Hospital, China.
Shuhong LiuDepartment of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China.
Gaungde ZhouDepartment of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China.
Na LiAdvanced Cell Diagnostics, 3960 Point Eden Way, Hayward, CA 94545, USA.
Junqi NiuDepartment of Hepatology, the First Hospital of Jilin University, Changchun, China. Electronic address: junqi_niu@163.com.
Lai WeiBeijing Tsinghua Changgung Hospital, Tsinghua University, China. Electronic address: weilai@mail.tsinghua.edu.cn.
Jingmin ZhaoDepartment of Pathology and Hepatology, the 5th Medical Center, Chinese PLA General Hospital, China. Electronic address: jmzhao302@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether achieving sustained virological response (SVR) in patients with hepatitis C attains complete elimination of hepatitis C virus (HCV) is unknown, because occult HCV infection (OCI), defined as the detection of HCV-RNA in hepatocytes or peripheral blood mononuclear cells (PBMC) in absence of serum HCV-RNA, may occur. We thus investigated the prevalence and clinical relevance of OCI.

methodsSubjects from three hospitals who had achieved serum HCV clearance, including 60 of Direct-acting antiviral agents (DAAs) induced SVR, 50 of pegylated interferon plus ribavirin (PR) induced SVR, and 30 of spontaneous resolution, were subjected to detect HCV-RNA in liver by robust RNAscope assay and PBMC by qPCR. Paired liver biopsies at baseline and at SVR24 were analyzed.

resultsOCI was detected in 16 of 140 subjects (11.4%), with 15.0% in DAA-based group, 10.0% in PR group and 6.7% in spontaneously resolved group. In DAA-based subgroups, the incidence of OCI was gradually increased in group of solely DAA(s) therapy, combining DAA and PR therapy and combining DAA and ribavirin therapy. OCI is more frequent in patients with genotype 3. No correlation between baseline viral load, interleukin-28B genotype, baseline transaminases, post-SVR transaminases and OCI were found. However, OCI was significantly linked with severity of fibrosis and active inflammation at post-SVR, even considering basal fibrosis status. In addition, both the magnitude and the frequency of fibrosis regression were lower in patients with OCI than in those without OCI. In the multivariate analysis, PR therapy was identified an independent negative prognostic factor for both hepatic inflammation (P = .022) and fibrosis regression (P = .015). Importantly, we found HCV relapse in one of the OCI patients at 48 weeks after the end of PR treatment.

conclusionsHCV-RNA can persist in hepatocytes and/or PBMC in a certain of patients who achieved spontaneous or treatment-induced HCV RNA clearance from serum and associated with persistent histological abnormality. Our findings provide new insights into cure of HCV and could influence the following-up scenario after SVR.

Indexed as

Viral LoadAdultAgedAntiviral AgentsBiopsyFemaleHepacivirusHepatitis CHumansLiverLiver Function TestsMaleMiddle AgedRNA, ViralSustained Virologic ResponseTreatment OutcomeAntiviral AgentsRNA, ViralDirect-acting antiviral agentsHepatic pathologyLiver fibrosisOccult hepatitis CRNAscope assay

Identifiers

PMID31345785
PMCPMC6711338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.